MERCY VIATOR: Open Payments
NPI 1467914077 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,848 in 165 payments from 22 companies in 2025. Trend: 2023 $3,986 · 2024 $4,211 · 2025 $3,848
Food & beverage: $3,473Consulting: $375
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 26 | $599 |
| LEO Pharma Inc. | 6 | $498 |
| ABBVIE INC. | 16 | $370 |
| GENZYME CORPORATION | 9 | $342 |
| Organon LLC | 33 | $321 |
| Incyte Corporation | 16 | $283 |
| Galderma Laboratories, L.P. | 9 | $228 |
| E.R. Squibb & Sons, L.L.C. | 9 | $218 |
| Lilly USA, LLC | 3 | $199 |
| Amgen Inc. | 9 | $152 |
Products named: ADBRY, DUPIXENT, COSENTYX, OPZELURA, SKYRIZI, Sotyktu, NEMLUVIO, Rhapsido.
Industry payments across MD — which companies pay providers there.
